Charles River Laboratories Return on Tangible Equity 2010-2025 | CRL
Current and historical return on tangible equity values for Charles River Laboratories (CRL) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Charles River Laboratories Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $-0.04B | $-0.33B | 21.11% |
| 2024-12-31 | $0.01B | $-0.10B | -7.05% |
| 2024-09-30 | $0.42B | $-0.12B | -192.71% |
| 2024-06-30 | $0.44B | $-0.15B | -144.35% |
| 2024-03-31 | $0.44B | $-0.25B | -107.12% |
| 2023-12-31 | $0.47B | $-0.36B | -88.10% |
| 2023-09-30 | $0.47B | $-0.46B | -72.39% |
| 2023-06-30 | $0.48B | $-0.59B | -81.86% |
| 2023-03-31 | $0.50B | $-0.75B | -96.82% |
| 2022-12-31 | $0.49B | $-0.82B | -133.70% |
| 2022-09-30 | $0.44B | $-0.20B | -93.71% |
| 2022-06-30 | $0.44B | $-0.27B | -86.35% |
| 2022-03-31 | $0.42B | $-0.15B | -80.88% |
| 2021-12-31 | $0.39B | $-1.23B | -90.88% |
| 2021-09-30 | $0.40B | $-0.39B | -649.18% |
| 2021-06-30 | $0.40B | $-0.31B | 788.06% |
| 2021-03-31 | $0.38B | $0.21B | 328.23% |
| 2020-12-31 | $0.36B | $0.24B | 1693.02% |
| 2020-09-30 | $0.30B | $0.05B | -885.29% |
| 2020-06-30 | $0.27B | $-0.05B | -425.10% |
| 2020-03-31 | $0.25B | $-0.16B | -274.79% |
| 2019-12-31 | $0.25B | $0.02B | -854.24% |
| 2019-09-30 | $0.23B | $-0.07B | -667.63% |
| 2019-06-30 | $0.22B | $-0.16B | -572.55% |
| 2019-03-31 | $0.23B | $0.09B | -576.10% |
| 2018-12-31 | $0.23B | $0.00B | -22700.00% |
| 2018-09-30 | $0.14B | $-0.08B | 320.47% |
| 2018-06-30 | $0.13B | $-0.17B | 127.72% |
| 2018-03-31 | $0.13B | $0.24B | 74.89% |
| 2017-12-31 | $0.12B | $0.18B | 98.20% |
| 2017-09-30 | $0.20B | $0.15B | 261.39% |
| 2017-06-30 | $0.18B | $0.12B | 404.40% |
| 2017-03-31 | $0.17B | $0.05B | 1081.97% |
| 2016-12-31 | $0.16B | $-0.02B | 209.46% |
| 2016-09-30 | $0.14B | $0.03B | 103.27% |
| 2016-06-30 | $0.14B | $0.00B | 106.21% |
| 2016-03-31 | $0.16B | $0.29B | 82.89% |
| 2015-12-31 | $0.15B | $0.23B | 93.02% |
| 2015-09-30 | $0.15B | $0.01B | 77.23% |
| 2015-06-30 | $0.14B | $0.22B | 58.64% |
| 2015-03-31 | $0.13B | $0.19B | 53.85% |
| 2014-12-31 | $0.13B | $0.34B | 44.21% |
| 2014-09-30 | $0.12B | $0.22B | 41.70% |
| 2014-06-30 | $0.12B | $0.20B | 37.20% |
| 2014-03-31 | $0.11B | $0.39B | 31.28% |
| 2013-12-31 | $0.10B | $0.33B | 31.35% |
| 2013-09-30 | $0.10B | $0.34B | 31.51% |
| 2013-06-30 | $0.09B | $0.33B | 29.64% |
| 2013-03-31 | $0.10B | $0.31B | 31.84% |
| 2012-12-31 | $0.10B | $0.31B | 33.05% |
| 2012-09-30 | $0.11B | $0.30B | 38.60% |
| 2012-06-30 | $0.10B | $0.28B | 39.96% |
| 2012-03-31 | $0.10B | $0.27B | 41.11% |
| 2011-12-31 | $0.11B | $0.24B | 44.04% |
| 2011-09-30 | $-0.26B | $0.24B | -93.32% |
| 2011-06-30 | $-0.31B | $0.28B | -95.63% |
| 2011-03-31 | $-0.32B | $0.24B | -73.89% |
| 2010-12-31 | $-0.34B | $0.37B | -60.41% |
| 2010-09-30 | $0.02B | $0.39B | 3.72% |
| 2010-06-30 | $0.09B | $0.75B | 12.02% |
| 2010-03-31 | $0.11B | $0.73B | 15.34% |
| 2009-12-31 | $0.11B | $0.71B | 17.06% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $7.320B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $143.611B | 26.64 |
| CVS Health (CVS) | United States | $83.126B | 10.34 |
| Elevance Health (ELV) | United States | $66.200B | 8.90 |
| Cencora (COR) | United States | $55.265B | 18.41 |
| DiDi Global (DIDIY) | China | $26.074B | 27.70 |
| Labcorp Holdings (LH) | United States | $22.092B | 17.56 |
| Natera (NTRA) | United States | $20.748B | 0.00 |
| BioMerieux (BMXMF) | France | $17.652B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $14.860B | 0.00 |
| CochLear (CHEOY) | Australia | $13.234B | 0.00 |
| ICON (ICLR) | Ireland | $12.795B | 12.31 |
| Solventum (SOLV) | United States | $12.697B | 13.13 |
| Medpace Holdings (MEDP) | United States | $12.202B | 32.29 |
| Viatris (VTRS) | United States | $11.385B | 4.02 |
| Revvity (RVTY) | United States | $10.080B | 17.76 |
| Sonic Healthcare (SKHHY) | Australia | $8.961B | 0.00 |
| HealthEquity (HQY) | United States | $8.047B | 35.25 |
| Avantor (AVTR) | United States | $7.840B | 11.50 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.569B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $4.828B | 32.48 |
| Sotera Health (SHC) | United States | $3.965B | 22.17 |
| Amplifon S.p.A (AMFPF) | Italy | $3.937B | 21.83 |
| BrightSpring Health Services (BTSG) | United States | $3.681B | 28.08 |
| Surgery Partners (SGRY) | United States | $3.031B | 38.13 |
| GeneDx Holdings (WGS) | United States | $3.020B | 69.16 |
| Alignment Healthcare (ALHC) | United States | $2.873B | 0.00 |
| Concentras Parent (CON) | United States | $2.771B | 17.58 |
| Organon (OGN) | United States | $2.397B | 2.61 |
| Progyny (PGNY) | United States | $1.959B | 41.54 |
| Premier (PINC) | United States | $1.921B | 14.58 |
| Ardent Health (ARDT) | United States | $1.702B | 6.57 |
| PACS (PACS) | United States | $1.698B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.248B | 8.33 |
| GoodRx Holdings (GDRX) | United States | $1.239B | 20.41 |
| Teladoc Health (TDOC) | United States | $1.230B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.008B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| Embecta (EMBC) | United States | $0.718B | 4.21 |
| AMN Healthcare Services Inc (AMN) | United States | $0.660B | 8.17 |
| CareDx (CDNA) | United States | $0.637B | 11.73 |
| Performant Healthcare (PHLT) | United States | $0.602B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.586B | 201.00 |
| So-Young (SY) | China | $0.506B | 0.00 |
| Omada Health (OMDA) | $0.490B | 0.00 | |
| Nutex Health (NUTX) | United States | $0.488B | 7.39 |
| Auna S.A (AUNA) | Luxembourg | $0.460B | 10.37 |
| Sonida Senior Living (SNDA) | United States | $0.460B | 0.00 |
| SBC Medicals (SBC) | United States | $0.456B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.447B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.421B | 0.00 |
| Enhabit (EHAB) | United States | $0.386B | 25.40 |
| Oncology Institute (TOI) | United States | $0.382B | 0.00 |
| Agilon Health (AGL) | United States | $0.362B | 0.00 |
| LifeMD (LFMD) | United States | $0.323B | 0.00 |
| Beauty Health (SKIN) | United States | $0.238B | 0.00 |
| Shoulder Innovations (SI) | $0.189B | 0.00 | |
| DocGo (DCGO) | United States | $0.160B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.106B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.093B | 0.00 |
| KindlyMD (NAKA) | United States | $0.073B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Biodesix (BDSX) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.048B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.038B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.037B | 0.00 |
| ModivCare (MODV) | United States | $0.035B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.011B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.010B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |